Presentation is loading. Please wait.

Presentation is loading. Please wait.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Published byCorey Hall Modified over 5 years ago

Similar presentations

Presentation on theme: "Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects."— Presentation transcript:

1 Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2=8.71, P=0.367, I2=8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2=11.0, P=0.20, I2=27.2%. CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians’ Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women’s Health Study. Michael Pignone et al. Dia Care 2010;33: ©2010 by American Diabetes Association

Download ppt "Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects."

Similar presentations

ASCOT Lancet, April 2003 n=10,305 Evidence for: primary prevention of CHD and stroke in high risk, middle aged, hypertensive, male patients with TC

ASCOT Lancet, April 2003 n=10,305 Evidence for: primary prevention of CHD and stroke in high risk, middle aged, hypertensive, male patients with TC
The ABC’s of the AHA/ACC Prevention Guidelines

The ABC’s of the AHA/ACC Prevention Guidelines
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.

Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.

The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.
Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.

Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Cardiovascular Risk Diabetes And Aspirin A Closer look into the evidence-base Howard Van IM2 Ahraaz Wyne IM1 The University of Western Ontario London Health.

Cardiovascular Risk Diabetes And Aspirin A Closer look into the evidence-base Howard Van IM2 Ahraaz Wyne IM1 The University of Western Ontario London Health.
6/5/2006 - 1 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risks of Progression of Retinopathy and Vision Loss.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risks of Progression of Retinopathy and Vision Loss.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:306-313.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Similar presentations

Ads by Google